Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings Inc.

Medpace Holdings ( ($MEDP) ) has issued an announcement. Effective June 1, 2026, Medpace Holdings, Inc. appointed long-time executive Brad W. Hansm...

Medpace Elevates Brad Hansman to Executive Operations Role

Medpace Holdings Inc ($MEDP) announced an update on their ongoing clinical study. The BEACON Phase III study, titled “A Randomized, Multi-center, D...

BEACON Phase III Rugonersen Trial Puts Medpace in Focus for Rare Disease Investors

The latest update is out from Medpace Holdings ( ($MEDP) ). At its May 15, 2026 annual meeting, Medpace Holdings, Inc. shareholders approved amendm...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MEDP	$466.79	+1.94%	284.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MEDP	$466.79	+1.9%	284.28K
3
4
5
6

MEDP

MEDP

Get Medpace Holdings Inc. Data in Excel

Get Medpace Holdings Inc. Data in Excel